Insulin Resistance: Cause or Consequence of Nonalcoholic Steatohepatitis?

Gastroenterology

Volumn 132, Issue 1, 2007, Pages 444-446

  Ahima, Rexford S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; METHIONINE; PIOGLITAZONE; S ADENOSYLMETHIONINE;

DIET; DYSLIPIDEMIA; EDITORIAL; EXERCISE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER CELL DAMAGE; LIVER FIBROSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 33846184713     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.11.048     Document Type: Editorial

References (21)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
2. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
3. Hui J.M., Kench J.G., Chitturi S., Sud A., Farrell G.C., Byth K., Hall P., Khan M., and George J. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38 (2003) 420-427
4. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., and Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
5. Utzschneider K.M., and Kahn S.E. The role of insulin resistance in non-alcoholic fatty liver disease. J Clin Endocrinol Metab 91 (2006) 4753-4761
6. Day C.P. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16 (2002) 663-678
7. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 123 (2002) 1702-1704
8. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., and Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 358 (2001) 893-894
9. Bugianesi E., Gentilcore E., Manini R., Natale S., Vanni E., Villanova N., David E., Rizzetto M., and Marchesini G. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005) 1082-1090
10. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., and Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
11. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., Doo E., Ghany M., Premkumar A., Park Y., Liang T.J., Yanovski J.A., Kleiner D.E., and Hoofnagle J.H. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
12. Ota T., Takamura T., Kurita S., Matsuzawa N., Kita Y., Uno M., Akahori H., Misu H., Sakurai M., Zen Y., Nakanuma Y., and Kaneko S. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132 (2007) 282-293
13. Kirsch R., Clarkson V., Shephard E.G., Marais D.A., Jaffer M.A., Woodburne V.E., Kirsch R.E., and Hall Pde L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 18 (2003) 1272-1282
14. Sahai A., Malladi P., Pan X., Paul R., Melin-Aldana H., Green R.M., and Whitington P.F. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 287 (2004) G1035-G1043
15. Rinella M.E., and Green R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 40 (2004) 47-51
16. Shima K., Zhu M., and Mizuno A. Pathoetiology and prevention of NIDDM lessons from the OLETF rat. J Med Invest 46 (1999) 121-129
17. Man Z.W., Hirashima T., Mori S., and Kawano K. Decrease in triglyceride accumulation in tissues by restricted diet and improvement of diabetes in Otsuka Long-Evans Tokushima fatty rats, a non-insulin-dependent diabetes model. Metabolism 49 (2000) 108-114
18. Trujillo M.E., and Scherer P.E. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257 (2005) 167-175
19. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., Yamashita S., Noda M., Kita S., Ueki K., Eto K., Akanuma Y., Froguel P., Foufelle F., Ferre P., Carling D., Kimura S., Nagai R., Kahn B.B., and Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8 (2002) 1288-1295
20. Samuel V.T., Liu Z.X., Qu X., Elder B.D., Bilz S., Befroy D., Romanelli A.J., and Shulman G.I. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279 (2004) 32345-32353
21. Ye J.M., Dzamko N., Cleasby M.E., Hegarty B.D., Furler S.M., Cooney G.J., and Kraegen E.W. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 47 (2004) 1306-1313